Changes in Lipid Profile Over 24 Months Among Adults on First-Line Highly Active Antiretroviral Therapy in the Home-Based AIDS Care Program in Rural Uganda
Nevirapine
Efavirenz
Stavudine
Dyslipidemia
Abacavir
DOI:
10.1097/qai.0b013e31815e7453
Publication Date:
2009-03-05T15:00:19Z
AUTHORS (10)
ABSTRACT
Background: Use of highly active antiretroviral therapy (HAART) has been linked to dyslipidemia and increased risk cardiovascular disease (CVD) in HIV-infected patients industrialized countries. The effects HAART on lipid metabolism among sub-Saharan Africans, for whom access is expanding, remain largely unknown. Methods: From July 2003 May 2004, 987 antiretroviral-naive with symptomatic HIV or a CD4 count <250 cells/mm3 were started the Home-Based AIDS Care (HBAC) Program Tororo, Uganda. HBAC provided weekly drug delivery field-based clinical monitoring. Nonfasting repository sera from subset 374 analyzed levels total cholesterol (TC), direct low-density lipoprotein (LDL-c), high-density (HDL-c), triglycerides (TG) at baseline (before HAART) after 12 24 months using Randox enzymatic kits (Crumlin, United Kingdom). Results: evaluated (49% women, mean age = 39 years, 124 cells/mm3, body mass index 19.7 kg/m2) received initial composed stavudine, lamivudine, either nevirapine (365 [98%]) efavirenz (9 [2%]). During months, 99 (26%) had single substitutions stavudine zidovudine 27 (7%) efavirenz. At baseline, serum concentrations 120 mg/dL TC, 53 LDL-c, 29 HDL-c, 123 TG; values generally comparable men women. treatment, TC by 31 mg/dL, LDL-c 26 HDL-c 19 whereas TC/HDL-c ratio decreased 4.6 3.4 (all changes, P < 0.001). TG initially then returned months. respectively, was ≥200 2% 10% patients, ≥130 1% 6%, <40 88% 41%, ≥150 23% 20%. Conclusions: Rural Ugandans advanced initiating nevirapine- efavirenz-based experienced infrequent elevations therapy. Increases substantial proportionally greater than increases levels. CVD how it affected changes this rural African population are However, we observed seem unlikely increase CVD.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (32)
CITATIONS (42)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....